Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Longeveron Inc (NQ: LGVN ) 3.290 +0.040 (+1.23%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Longeveron Inc < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > PFE, MRNA Stocks: What to Know as the FDA Approves New Booster Shots August 31, 2022 Pfizer (PFE) and Moderna (MRNA) stocks are in the news Wednesday as the FDA approves new booster shots for the Covid-19 Omicron variant. Via InvestorPlace Why Is Longeveron (LGVN) Stock on the Move Today? August 31, 2022 Longeveron (LGVN) stock is on the move Wednesday after the FDA granted its fast-track designation for heart treatment Lomecel-B. Via InvestorPlace Longeveron Shares Ascend As FDA Grants Fast Track Status To Congenital Heart Disease Candidate August 31, 2022 Longeveron (NASDAQ: LGVN) received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead drug Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS). Via Benzinga EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants August 31, 2022 The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart... Via Benzinga European Patent Office Issues Intent To Grant Longeveron Patent Related To Methods To Monitor Efficacy Of Lomecel-B™ Cell Therapy August 26, 2022 Longeveron Inc. (NASDAQ: LGVN) announced that the European Patent Office (EPO) had issued a notice of its intent to grant the Company a patent (EP Application No. Via Benzinga Longeveron: Q2 Earnings Insights August 12, 2022 Longeveron (NASDAQ:LGVN) reported its Q2 earnings results on Friday, August 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga Recap: Longeveron Q1 Earnings May 13, 2022 Longeveron (NASDAQ:LGVN) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga EXCLUSIVE: Longeveron's Heart Disease Cell Therapy Poised To Secure European Patent August 25, 2022 The European Patent Office has issued a notice of its intent to grant Longeveron Inc (NASDAQ: LGVN) a patent related to methods to treat endothelial dysfunction and monitor the efficacy of allogeneic... Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session August 24, 2022 Via Benzinga Earnings Scheduled For August 12, 2022 August 12, 2022 Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. Via Benzinga Longeveron Earnings Preview August 11, 2022 Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will... Via Benzinga Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry? August 09, 2022 According to Grand View Research, the global cell therapy market was valued at $7.8 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 14.5% between 2021 and 2028. Via Benzinga Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron August 02, 2022 Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN) Via Benzinga Aging Veterans May Have New Options As VA And Longeveron Make Progress On Clinical Research Of Aging Frailty Treatment July 28, 2022 The U.S. Department of Veterans Affairs (VA) partnered with Longeveron Inc. (NASDAQ: LGVN) to explore the clinical-stage biotech’s novel cell therapies as a potential treatment for aging frailty. Via Benzinga 7 Moonshot Investments Upending a $10 Trillion Industry July 08, 2022 Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. Via InvestorPlace This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday July 08, 2022 Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. Via Benzinga Why U.S. Stocks Are Trading Higher After Rise In Jobless Claims July 07, 2022 U.S. stocks traded higher this morning, following the release of data on initial jobless claims. Via Benzinga This EV Maker Stock Jumps More Than 9%, Here's 46 Stocks Moving In Thursday's Mid-Day Session July 07, 2022 Gainers United Maritime Corporation (NASDAQ: USEA) jumped 180.4% to $8.02. The company’s stock jumped 190% on Wednesday after completing its spin-off from Seanergy Maritime Holdings Corp. Via Benzinga 7 Ways to Prepare for a Recession: An Investor’s Guide June 24, 2022 There are plenty of ways to prepare for a recession. Here are seven ways you can make sure you're ready for whatever comes next. Via InvestorPlace Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It June 15, 2022 Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Via Benzinga How to Buy Stocks in a Recession May 16, 2022 The same strategies for buying stocks during a bull market don't apply during a recession. Learn what you need to do going forward. Via InvestorPlace The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product May 13, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Earnings Scheduled For May 13, 2022 May 13, 2022 Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million. Via Benzinga Longeveron's Earnings: A Preview May 12, 2022 Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-05-13. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday May 12, 2022 With the start of another day comes our breakdown of the biggest pre-market stock movers and this time it's for Thursday! Via InvestorPlace The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves May 10, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Follow the Insiders and Buy the Dip in These 3 Stocks May 06, 2022 These three biotech companies have all had insiders buying shares recently. That's a good sign for the future of their treatments. Via InvestorPlace Analyzing Longeveron Inc. - common stock's Short Interest April 19, 2022 Longeveron Inc. - common stock's (NASDAQ:LGVN) short percent of float has risen 35.04% since its last report. The company recently reported that it has 746.20 thousand shares sold... Via Benzinga 71 Biggest Movers From Yesterday April 27, 2022 Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... Via Benzinga 53 Biggest Movers From Yesterday April 21, 2022 Gainers ION Geophysical Corporation (NYSE: IO) shares surged 91.2% to settle at $0.6980 on Wednesday. ION Geophysical was awarded a five-year contract by Brunei Shell Petroleum... Via Benzinga < Previous 1 2 ... 5 6 7 8 9 10 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.